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Randomized Phase II Study of Palifermin for Reducing
Dysphagia in Patients Receiving Concurrent
Chemoradiotherapy for Locally Advanced Unresectable
Non-small Cell Lung Cancer
Wolfgang Schuette, MD, PhD,* Maciej J. Krzakowski, MD, PhD,† Bartomeu Massuti, MD,‡
Gregory A. Otterson, MD,§ Richard Lizambri, MD, Helen Wei, PhD, Dietmar P. Berger, MD, PhD,
and Yuhchyau Chen, MD, PhD¶
Introduction: Dysphagia is a common, dose-limiting toxicity of
combined chemoradiotherapy (CT/RT) in patients with locally ad-
vanced non-small cell lung cancer (NSCLC). This study assessed the
efficacy and safety of palifermin in reducing dysphagia from CT/RT
followed by consolidation chemotherapy (CT).
Methods: This randomized, double-blind, phase II trial enrolled
adults with unresectable stage III NSCLC. Subjects received weekly
paclitaxel (50 mg/m2) and carboplatin (AUC 2.0) with concurrent
daily radiation (RT) of 6000 to 6600 cGy, followed by consolidation
CT. Palifermin (n  49) or placebo (n  46) was administered
before starting concurrent CT/RT and once weekly for 6 weeks. The
primary end points were the incidence of grade 2 dysphagia and
safety.
Results: The incidence of grade 2 and 3 dysphagia was numer-
ically lower in palifermin subjects versus placebo subjects (61%
versus 70%; p  0.36; 22% versus 28%, p  0.50, respectively).
Mean duration of dysphagia (grade 2) was 25 days for palifermin
subjects and 32 days for placebo subjects (p  0.32). The incidence
of adverse events was similar in the two treatment groups, and
median overall survival and progression-free survival were not
adversely affected by palifermin treatment (overall survival: 513
versus 319 days; progression-free survival: 262 versus 235 days
for palifermin versus placebo arms, respectively). The palifermin
arm received more doses of CT per study design and significantly
more patients received RT doses 6000 cGy (84% versus 61%,
p  0.01).
Conclusions: The results of this exploratory trial suggest that
additional larger studies may be warranted to further evaluate the
effect of palifermin on dysphagia, exposure to CT/RT, and long-
term survival.
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Concurrent chemoradiotherapy (CT/RT) is a standardtreatment for locally advanced and unresectable non-
small cell lung cancer (NSCLC), as studies reported that,
compared with use of sequential therapy or radiotherapy (RT)
only, use of concurrent CT/RT was associated with longer
survival.1–3 Concurrent therapy, however, increases the risk
and severity of esophagitis and pneumonitis as well as the
rate of other treatment-induced toxicities.1,4–9
Esophagitis is a common adverse event (AE) in CT/RT
treatment of stage III NSCLC, with dysphagia as the primary
clinical symptom.10–12 Esophagitis may be severe and dis-
abling and may result in pain, weight loss, hospitalization,
and the need for a gastrostomy or jejunostomy tube for
enteral feeding.13 In some patients, RT and chemotherapy
(CT) interruptions that may have an adverse impact on tumor
control and survival are necessary to allow for healing of the
esophageal lining.13 Despite research into the potential of the
cyto- and radioprotective agent amifostine,14 there is no
effective treatment or preventive measure for RT-induced
esophagitis/dysphagia.
Keratinocyte growth factor (KGF) is an endogenous
protein in the fibroblast growth factor family that binds to the
KGF receptor. Binding of KGF to its receptor has been
reported to result in proliferation, differentiation, and migra-
tion of epithelial cells.15,16 Palifermin (Kepivance, Thousand
Oaks, CA) is the recombinant human form of KGF and has
been found to markedly reduce chemotherapy- and radiation-
induced injury to the mucosal lining of the oral cavity and the
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lower gastrointestinal tract in a variety of animal models of
CT, RT, and blood stem cell transplantation.17–19 Palifermin
has an indication to decrease the incidence and duration of
severe oral mucositis in patients with hematologic malignan-
cies receiving myelotoxic therapy requiring hematopoietic
stem cell support.20
This phase II, randomized, double-blind, placebo-con-
trolled study evaluated the efficacy and safety of weekly
palifermin 180 g/kg in reducing the incidence and duration
of dysphagia induced by CT/RT in patients with unresectable
stage III NSCLC.
PATIENTS AND METHODS
Study Design
In this multicenter, double-blind study, subjects were
screened for eligibility up to 6 weeks before the start of the
study and randomly assigned using an interactive voice re-
sponse system in a 1:1 ratio to palifermin or placebo. Subjects
were stratified by disease stage (stage IIIa versus IIIb),
Eastern Cooperative Oncology Group (ECOG) performance
status (0–1 versus 2), and estimated weight loss in the 3
months before study randomization (5% versus 5–10%).
All subjects received weekly paclitaxel (50 mg/m2) and
carboplatin (AUC 2.0), concurrent RT to a target of 6000 to
6600 cGy given as 200 cGy once daily for 30 to 33 fractions,
followed by two cycles of consolidation CT of paclitaxel (225
mg/m2) and carboplatin (AUC 6.0). Lyophilized palifermin
or placebo was supplied in 6.25-mg single-dose vials for
reconstitution with 1.2 ml sterile water. Subjects received
placebo or palifermin 180 g/kg intravenously 3 days before
initiation of concurrent CT/RT and then once weekly during
weeks 1 through 6, for a total of seven doses (Figure 1).
The primary end point was incidence of grade 2
dysphagia measured using the Common Terminology Criteria
for Adverse Events version 3.0 (CTCAE v3.0) dysphagia
scale. Secondary end points included duration (days) of grade
2 dysphagia, incidence and duration of severe (grade 3)
dysphagia, maximum severity of dysphagia, time to onset of
grade 2 dysphagia, time to onset of severe dysphagia,
change in ECOG performance status, and incidence of un-
planned breaks or discontinuations of RT. Safety end points
included incidence of chronic dysphagia (unresolved grade
2 dysphagia) at month 6, tumor response rate, progression-
free survival (PFS) and overall survival (OS), laboratory
abnormalities, and serum antipalifermin antibody formation.
Acute dysphagia was assessed twice weekly using
CTCAE v3.0 during weeks 1 through 12 and once weekly
after week 12 until dysphagia resolved to grade 1, up to
week 16. Tumor response was evaluated by computed tomog-
raphy scan or magnetic resonance imaging of the chest and
abdomen at the end of week 12, as determined by the
investigator. Positron emission tomography was permitted for
assessment of disease status. All subjects were followed for
disease progression, second primary tumors, other malignan-
cies, and OS until death or loss to follow-up.
Subjects
Subjects were recruited from 25 centers across the
United States and Europe. All subjects gave written informed
consent, and the study was approved by Institutional Review
Boards at participating centers. Eligible subjects were at least
18 years old, had unresectable stage IIIa or IIIb NSCLC with
a life expectancy of at least 6 months, an ECOG status of 0
to 2, and an estimated weight loss of 10% in the previous
3 months. Patients were ineligible if they had stage IV
disease; pleural or pericardial effusion estimated to be greater
than 100 ml; prior CT, RT, or surgery for NSCLC; planned
surgery to remove the tumor before completing the CT/RT
course; or prior invasive malignancy in the past 3 years,
except nonmelanomatous skin cancer.
Statistical Analysis
The primary objective of this study was to obtain
preliminary data on whether palifermin had activity in this
setting and indicate whether a larger phase 3 trial was
FIGURE 1. Study design and
treatment schedule. P, paclitaxel; C,
carboplatin; PAL, palifermin; PBO,
placebo; Wk, week.
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warranted. As this was an exploratory analysis, the sample
size was not powered to achieve statistical significance.
Efficacy analyses included all subjects who were ran-
domized (intent-to-treat population), and data were analyzed
based on the treatment group as per randomization. Missing
data after discontinuation were imputed for the incidence and
duration of dysphagia. Subjects with no dysphagia evalua-
tions were assigned a grade 2 dysphagia. Duration of
dysphagia was calculated in days from onset (first occurrence
of grade 2) to resolution (grade 1). Safety analyses
included all subjects who received at least one dose of study
drug, and data were analyzed based on treatment actually
received. Following advisement from one Institutional Re-
view Board, four randomized subjects (two each in the
placebo and palifermin group) from one site were excluded
from the study, and all data were reanalyzed accordingly.
Summary statistics were provided by treatment group.
For continuous variables, the mean, SD, median, and range
were calculated. For categorical variables, the frequency and
percentage were computed. The generalized Cochran-Mantel-
Haenszel (CMH) method for general association, adjusted for
the randomization stratification factors, was performed to
compare the incidence- and duration-type end points between
the palifermin and placebo groups. The time-to-onset end
points were analyzed using the Kaplan-Meier method and
log-rank test stratified by randomization factors to compare
the treatment groups. The time to onset of dysphagia was
calculated in days relative to the date of randomization. The
OS and PFS time were calculated in days relative to the day
when a subject received first dose of the study drug.
AEs were coded according to the Medical Dictionary
for Regulatory Activities (MedDRA). Long-term safety data
of OS and PFS were analyzed using the Kaplan-Meier
method.
Post hoc analyses were undertaken to gain insight into
subjects who received the full RT dose (6000 cGy) in each
treatment group. The CMH method for general association,
adjusted for randomization stratification factors, was used to
compare the proportion of subjects who received full dose of
RT between the treatment groups.
RESULTS
Of 95 subjects enrolled, 49 were randomized to pali-
fermin treatment and 46 to placebo treatment and were
included in the intent-to-treat population (Figure 2). A total of
40 subjects (82%) in the palifermin group and 28 (61%) in the
placebo group completed the study. The most common rea-
sons for study discontinuation were withdrawal of consent
(palifermin: three subjects, 6%; placebo: five subjects, 11%)
and AEs (palifermin: two subjects, 4%; placebo: five sub-
jects, 11%). The demographic and other baseline character-
istics were similar in the palifermin and placebo groups
(Table 1).
The incidence of grade 2 dysphagia was numerically
lower in the palifermin group (30 subjects, 61%) than in the
placebo group (32 subjects, 70%, p 0.36) (Figure 3). Lower
values were also reported in the palifermin group than in the
placebo group for the incidence of grade 3 dysphagia (11
subjects [22%] versus 13 subjects [28%]; p  0.50) (Figure
3), the mean number of days of grade 2 dysphagia (25.3
versus 32.4 days; p  0.32), and the incidence of unplanned
RT breaks (9 subjects [18%] versus 15 subjects [33%]; p 
0.11). The overall distribution of fewer days of grade 2
dysphagia for subjects receiving palifermin is shown in Fig-
ure 4. Median time to onset of grade 2 dysphagia was 45
days in the palifermin group and 31 days in the placebo group
(p  0.21). Grade 4 dysphagia was reported for one subject
in the palifermin group; this event did not result in drug or
study discontinuation.
Performance status of subjects deteriorated more in the
placebo group than in the palifermin group, with a maximal
mean (SD) ECOG score increase through week 12 of 0.9
(1.1) in the palifermin group and 1.5 (1.3) in the placebo
group (p  0.06).
FIGURE 2. CONSORT diagram.
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Overall tumor response rate was numerically better for
subjects in the palifermin group; 33 of 48 subjects (69%) in
the palifermin group and 22 of 46 subjects (48%) in the
placebo group had a complete or partial response.
Subjects in the palifermin group received more doses of
study drug (palifermin) than subjects in the placebo group: 42
subjects (86%) in the palifermin group and 30 (65%) in the
placebo group received seven or eight doses. This was also
reflected in the mean (SD) number of doses received in the
palifermin group, with 6.7 (1.2) doses received by the pali-
fermin group and 5.8 (2.0) doses received in the placebo
group. Mean (SD) relative dose intensity (RDI) showed
similar exposure differences: 95% (17%) for the palifermin
group and 83% (29%) for the placebo group.
Subjects in the palifermin group had greater exposure
to RT than subjects in the placebo group. The mean (SD) total
dose of RT for subjects who received palifermin was 5830
(836) cGy and 5220 (1611) cGy for the placebo group. The
number of subjects receiving a cumulative RT dose 6000
cGy was 41 (84%) in the palifermin group and 28 (61%) in
the placebo group (p  0.01). These differences in dose were
also reflected in the mean (SD) RDI for RT, which was 92%
(14%) for the palifermin group and 82% (25%) for the
placebo group. The distribution of cumulative RT dose re-
ceived by treatment group is shown in Figure 5.
When analyzed by RT dose received, the incidence of
grade 2 dysphagia was numerically lower in the palifermin
group (27/41 subjects, 66%) than in the placebo group (22/28
subjects, 79%) in subjects receiving a cumulative RT dose
6000 cGy (p  0.29, Fisher’s exact test). Similar findings
were observed in the incidence of grade 3 dysphagia for
subjects receiving an RT dose 6000 cGy in the palifermin
(8/41, 20%) and placebo (10/28, 36%) groups (p  0.17,
Fisher’s exact test).
Subjects in the palifermin group also received more
doses of paclitaxel and carboplatin than subjects in the
placebo group: 35 subjects (71%) in the palifermin group and
28 (61%) in the placebo group received six or more doses.
The mean (SD) number of total doses was 5.8 (1.0) for
the palifermin group and 5.1 (1.7) for the placebo group. The
mean (SD) RDI for carboplatin was 93% (22%) for the
palifermin group and 74% (27%) for the placebo group, and
for paclitaxel it was 90% (15%) for the palifermin group and
81% (26%) for the placebo group. Consolidation CT with
paclitaxel and carboplatin occurred during weeks 7 to 11. The
exposure to this CT regimen was similar for the placebo and
palifermin groups.
Adverse Events
One subject in the palifermin group did not receive
study drug and was therefore not included in the safety
analysis. Of the 94 subjects in the safety subset, AEs were
experienced by all subjects except one in the placebo group.
Serious AEs were reported for 51 subjects (54%) in the safety
subset: 21 subjects (44%) in the palifermin group and 30
(65%) in the placebo group. Fatal AEs were reported for 7
subjects (7%), 2 of the 48 subjects in the palifermin group
(4%) and 5 of the 46 subjects (11%) in the placebo group;
none of these AEs was considered by the investigator to be
related to palifermin treatment. Fatal AEs included pneumo-
nia (two subjects, placebo), disease progression (one subject,
palifermin), sudden death (one subject, placebo), hypoxia
TABLE 1. Subject Characteristics and Disease State
Placebo
(N  46)
Palifermin
(N  49)
Gender, male 32 (70) 34 (69)
Race/ethnicity
White 43 (93) 43 (88)
Black 2 (4) 2 (4)
Other 1 (2) 4 (8)
Age, yr, mean (SD) 64.2 (7.7) 61.6 (9.8)
AJCC stage
IIIa 14 (30) 19 (39)
IIIb 32 (70) 30 (61)
T stagea
T1 4 (9) 3 (6)
T2 18 (39) 18 (37)
T3 9 (20) 10 (20)
T4 15 (33) 17 (35)
N stage
N0/N1 9 (20) 8 (16)
N2 19 (41) 27 (55)
N3 18 (39) 14 (29)
ECOG PS
0–1 44 (96) 47 (96)
2 2 (4) 2 (4)
Weight loss over last 3 mo
5% 35 (76) 37 (76)
5–10% 11 (24) 12 (24)
Current tobacco use 16 (34) 14 (29)
Current alcohol use 14 (30) 13 (27)
Unless otherwise indicated, values are given as n (%).
a One subject with nodal disease, unknown T stage.
AJCC, American Joint Committee on Cancer; ECOG PS, Eastern Cooperative
Oncology Group performance status.
FIGURE 3. Incidence of grade 2 and 3 dysphagia.
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(one subject, palifermin), neoplasm progression (one subject,
placebo), and circulatory collapse (one subject, placebo).
Treatment-related AEs were reported for 20 subjects:
13 of 48 subjects (27%) in the palifermin group and 6 of 46
(13%) in the placebo group (Table 2). Treatment-related
serious AEs were reported for two subjects (4%) in the
palifermin group and four subjects (9%) in the placebo group.
All of these events occurred in one subject each; none of
these were fatal.
The incidence of clinical laboratory values that were
considered AEs was similar between the treatment groups.
No subject had a positive result for antipalifermin neutraliz-
ing antibodies during this study.
In the long-term safety evaluation at month 6, subjects
in the placebo group had a numerically higher incidence of
tumor progression or recurrence than subjects in the palifer-
min group: 9 of 48 subjects (19%) in the palifermin group and
12 of 46 subjects (26%) in the placebo group. OS and PFS
were not adversely affected by palifermin treatment, with
median time to death of 319 days for the placebo group and
513 days for the palifermin group (p  0.42; hazard ratio
[HR] 0.80, 95% confidence interval [CI] 0.44–1.50) (Figure
6A). Median time to disease progression or death was 262
days for the palifermin group and 235 days for the placebo
group (p  0.20; HR 0.74, CI 0.43–1.28) (Figure 6B). An
ad-hoc analysis adjusted for tumor stages (N stage and AJCC
stage) resulted similar hazard ratios (0.81 for OS and 0.74 for
PFS).
DISCUSSION
This was the first study to assess the effect of palifermin
on dysphagia in subjects with unresectable stage III NSCLC
receiving concurrent CT/RT. There was a numerical decrease
in the incidence and duration of dysphagia and a delay in time
to onset of dysphagia in the palifermin arm, although this was
not statistically significant in this exploratory trial. In addi-
tion, the palifermin group received more exposure than the
placebo group to RT/CT, and post hoc analyses indicated that
more subjects in the palifermin group than in the placebo
group received the full RT dose (6000 cGy) (p  0.01).
Greater exposure to RT/CT in the palifermin group is not
surprising as discontinuation was more common in the pla-
cebo group, with 39% of subjects discontinuing in the pla-
cebo group compared with 18% in the palifermin group,
hence these subjects did not receive the scheduled RT/CT
doses. Lower serious AEs, AEs leading to study discontinu-
FIGURE 4. Distribution of mean duration of
grade 2 dysphagia by treatment group.
FIGURE 5. Distribution of cumulative radiation dose
received.
TABLE 2. Summary of Adverse Events
Placebo
(N  46)
Palifermin
(N  48)
Adverse events (AEs) 45 (98) 48 (100)
Serious AEs 30 (65) 21 (44)
Treatment-related AEs 6 (13) 13 (27)
Serious AEs 4 (9) 2 (4)
Most frequent (5%) treatment-related AEs
Rash 3 (7) 2 (4)
Diarrhea 0 (0) 3 (6)
Erythema 0 (0) 3 (6)
Flushing 0 (0) 3 (6)
Incidence of second primary tumors 0 (0) 0 (0)
Unresolved grade 2 dysphagia at month 6 2 (4) 0 (0)
On-study death 5 (11) 2 (4)
Values are given as n (%).
Journal of Thoracic Oncology • Volume 7, Number 1, January 2012 Randomized Phase II Study of Palifermin in Dysphagia
Copyright © 2011 by the International Association for the Study of Lung Cancer 161
ation, and fewer on-study deaths were observed in the pali-
fermin subjects compared with the placebo group, which may
also have affected the number of doses received. Neverthe-
less, of those who received the full RT dose in either treat-
ment group, a smaller percentage of palifermin subjects
experienced grade 2 or 3 dysphagia. Increased exposure
to CT and RT may have contributed to better ECOG perfor-
mance status over time, higher response rates, and numerical
difference in survival. No major acute or chronic safety
concerns were identified.
Studies have suggested a relationship between higher
doses of RT and CT and local tumor control.21–24 A minimum
dose of 6000 cGY is considered a standard therapy following
the results of the Radiation Therapy Oncology Group
(RTOG) 73-01 study in which the intrathoracic failure rate
was 33% at 3 years for NSCLC patients treated with 6000
cGy, 42% for those treated with 5000 cGy, and 52% for
patients treated with 4000 cGy in a continuous course.24
While the standard RT dose (6000 cGy) has remained un-
changed for the past 30 years, higher doses are being inves-
tigated for the effect on local control and survival, including
the phase III RTOG 0617 study.25 Several groups have
performed RT dose escalation trials in NSCLC patients and
reported results supporting the safety of 7400 cGy26–29;
however, studies also indicate that higher doses are associ-
ated with increased toxicity.30,31
Improved survival has also been reported in patients
receiving higher CT dose intensity during concurrent CT/
RT.23 In addition, clinical trials have shown that, compared
with sequential therapy, concurrent CT/RT is associated with
longer survival in patients with unresectable stage III
NSCLC,1–4 with an expected 4-year survival rate of 21% for
RT doses to 6000 cGy with concurrent CT in patients with
good performance status and minimal weight loss.1 However,
concurrent CT/RT is more toxic than the sequential approach,
with an increased risk of RT-induced side effects, including
esophagitis and dysphagia.1,4–9 Severe acute esophageal tox-
icity (grade 3–4) increased from 3% with the sequential
approach to 18% with concurrent RT/CT, with a relative risk
of 5.7 (p  0.0001).4 The current treatment options of
CT/RT-induced esophagitis are symptomatic. Inadequate
management can lead to pain, nutritional deficits, reduction in
dose intensity, and unplanned treatment breaks.13,30 Amifos-
tine has been investigated as a potential treatment option to
reduce the rate of esophagitis in patients receiving concurrent
RT/CT for locally advanced or inoperable NSCLC. Random-
FIGURE 6. Kaplan-Meier curves for
overall survival and progression-free
survival: overall survival (A), progres-
sion-free survival (B).
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ized clinical trials reported mixed results on the effectiveness
of amifostine in reducing the incidence of esophagitis in this
setting,10,32 and a large-scale trial (RTOG 98-01) failed to
demonstrate a reduction in risk. Thus, there continues to be a
lack of an effective therapy to reduce the risk of esophagitis
despite the clinical need.
Palifermin is an epithelial growth factor, and some
epithelial tumors may express the KGF receptor; therefore, it
is theoretically possible for palifermin administration to in-
terfere with disease outcomes, either through direct stimula-
tion of tumor growth or through interference with the tumor
response to cytotoxic treatment. The results of our study
suggest that palifermin did not adversely affect disease out-
comes in these patients. Unexpectedly, compared with the
placebo group, the palifermin group appeared to have a better
response rate, OS, and PFS, although the difference did not
reach statistical significance. The significantly higher cumu-
lative intensity of CT and higher RT doses may have con-
tributed to these outcomes.
The activity of palifermin has been investigated previ-
ously in other solid tumors.33,34 A phase II study of palifermin
and concurrent chemoradiation in head and neck squamous
cell carcinoma reported that palifermin (60 g/kg for 10
doses) was well tolerated and indicated activity with re-
ductions observed in mucositis, dysphagia, and xerostomia
during hyperfractionated radiotherapy but not standard
radiotherapy.33 In a separate phase II study, a significant
reduction in oral mucositis was reported with palifermin
administration (40 g/kg for 3 consecutive days) in pa-
tients with metastatic colorectal cancer treated with fluo-
rouracil-based chemotherapy.34
This exploratory study has several limitations. The
sample size was not powered to achieve statistical signifi-
cance, different RT techniques were used, and prespecified
data evaluations were complemented by post hoc analyses.
Fewer patients in the placebo group completed the study,
which may have affected the results. While missing values
for the incidence and duration of dysphagia were imputed for
subjects who discontinued the study, doses of RT and CT
were recorded until discontinuation. Hence, the higher cumu-
lative doses of RT and CT observed in the study in the
palifermin group are not unexpected, given that more subjects
in the palifermin arm completed the study. Consequently, the
results of this trial have to be interpreted with a hypothesis-
generating approach.
In conclusion, the results of this exploratory trial sug-
gest that additional larger studies may be warranted to further
evaluate the effect of palifermin on dysphagia, exposure to
RT/CT, and long-term survival.
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